Abstract: A monoclonal antibody specifically binding to human and monkey CD38 antigens or a derivative thereof includes: antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region having amino acid sequences as set forth in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region having amino acid sequences as set forth in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable pharmaceutical preparation, administered alone or combined with other therapeutic means such as chemotherapy drugs, for treating tumors with positive CD38 expression, such as human myeloma and human lymphoma.

Abstract: A monoclonal antibody or a derivative thereof that binds to a human TIGIT antigen with high-affinity and antagonistically inhibits the binding of TIGIT to a ligand thereof such as CD155 is provided. Amino acid sequences of antigen complementarity-determining regions CDR-L1, CDR-L2 and CDR-L3 of an antibody light chain variable region, and amino acid sequences of antigen complementarity-determining regions CDR-H1, CDR-H2 and CDR-H3 of an antibody heavy chain variable region are specified. Further, a humanization preparation method for the antibody and amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody are provided. The antibody or the derivative thereof can serve as an ingredient of a pharmaceutical composition or can be prepared into an appropriate drug preparation, and administered alone or in combination with other medications, such as an anti-PD-1 monoclonal antibody, or treatment means, for treating diseases such as tumors.

Abstract: A monoclonal antibody or a derivative thereof that binds to a human TIGIT antigen with high-affinity and antagonistically inhibits the binding of TIGIT to a ligand thereof such as CD155 is provided. Amino acid sequences of antigen complementarity-determining regions CDR-L1, CDR-L2 and CDR-L3 of an antibody light chain variable region, and amino acid sequences of antigen complementarity-determining regions CDR-H1, CDR-H2 and CDR-H3 of an antibody heavy chain variable region are specified. Further, a humanization preparation method for the antibody and amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody are provided. The antibody or the derivative thereof can serve as an ingredient of a pharmaceutical composition or can be prepared into an appropriate drug preparation, and administered alone or in combination with other medications, such as an anti-PD-1 monoclonal antibody, or treatment means, for treating diseases such as tumors.

Abstract: Disclosed herein is a monoclonal antibody or a derivative thereof that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.

Abstract: A monoclonal antibody or a derivative thereof which can antagonize and inhibit the binding of human PD-1 antigen to its ligand: the amino acid sequences of CDR1, CDR 2 and CDR 3 in the light chain variable region of the antibody are shown in SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, while the amino acid sequences of CDR 1, CDR 2 and CDR 3 in the heavy chain variable region are shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. A humanization preparation process for the antibody and the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody.

Abstract: A monoclonal antibody specifically binding to human and monkey CD38 antigens or a derivative thereof includes: antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region having amino acid sequences as set forth in SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively; and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region having amino acid sequences as set forth in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable pharmaceutical preparation, administered alone or combined with other therapeutic means such as chemotherapy drugs, for treating tumors with positive CD38 expression, such as human myeloma and human lymphoma.

Abstract: Disclosed herein is a monoclonal antibody or a derivative thereof that specifically hinds to human plasmalemma vesicle-associated protein (PLVAP, PV-1), including antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region, and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The monoclonal antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable medicament, administered alone or combined with other medications such as anti-VEGF monoclonal antibody and the like, for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases.

Abstract: A monoclonal antibody or a derivative thereof which can antagonize and inhibit the binding of human PD-1 antigen to its ligand: the amino acid sequences of CDR1, CDR 2 and CDR 3 in the light chain variable region of the antibody are shown in SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, while the amino acid sequences of CDR 1, CDR 2 and CDR 3 in the heavy chain variable region are shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. A humanization preparation process for the antibody and the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody.

Abstract: A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.

Abstract: A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial cell growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.

Abstract: An image data correction apparatus has a motion information acquisition section, a correction section, and a composition section. The motion information acquisition section acquires motion information indicating spatial distribution of the magnitude of motion, in actual space, of a to-be-imaged portion of a subject. Based on the motion information, the correction section performs correction, which is different from correction in a second region, in a first region of image data collected by a scan by magnetic resonance imaging. The composition section composes individual image data of the first region and the second region that are corrected by the correction section.